# SUPERIOR trial: 18% vs 28.3% atrial arrhythmia recurrence after ablation on sacubitril/valsartan

- Published: 2026-11-08 23:28 UTC
- Section: Life & Health › Medicine
- Tags: SUPERIOR trial, atrial fibrillation recurrence, catheter ablation, sacubitril/valsartan, valsartan, hypertension, AHA Scientific Sessions 2026, atrial tachyarrhythmia, randomized trial
- URL: https://realtech.media/news/rt-447b1b525473adde0e03c42d_superior_trial_18/

**In a randomized open-label trial of 320 older hypertensive patients in China, arrhythmia recurred less often after ablation on sacubitril/valsartan. The data are preliminary.**

![SUPERIOR trial: 18% vs 28.3% atrial arrhythmia recurrence after ablation on sacubitril/valsartan](https://realtech.media/media/2026/11/056b48484d61000b.webp)
*ad-hoc-news.de*

Results of the SUPERIOR trial were presented on 6 November 2026 at the American Heart Association Scientific Sessions in Chicago, according to ad-hoc-news.de. The study compared a combination drug regimen with standard treatment in older patients with hypertension who had undergone catheter ablation for atrial fibrillation [1].

## Trial design and patients

The randomized trial enrolled 320 adults from China aged 55 or older. The mean age was 68 years and 41.2% of participants were women. About 66.6% had paroxysmal atrial fibrillation. All patients underwent catheter ablation between February 2023 and January 2025 [1].

One group received sacubitril/valsartan at 100 mg once daily. The control group received valsartan monotherapy at 80 mg once daily. The primary endpoint was documented atrial tachyarrhythmias over a 12-month follow-up [1].

## Recurrence and blood pressure

After 12 months, documented recurrence of atrial arrhythmias was 18% in the sacubitril/valsartan group and 28.3% in the valsartan group [1].

Blood pressure effects were comparable. Systolic pressure fell by about 10 mm Hg in both groups, and 24-hour ambulatory monitoring showed no significant difference between them. According to the data, the better rhythm stability under the combination therapy was therefore not accompanied by a notably larger overall blood pressure reduction [1].

## Limitations

The results are preliminary. They were presented as a conference abstract and have not yet gone through regular peer review [1].

The study materials also note methodological limits. The trial was open-label, with intermittent rhythm monitoring. The cohort was limited to older hypertensive patients in China, so applicability to other patient groups requires further clinical verification [1].

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/wissenschaft/herzrhythmus-nach-ablation-18-statt-28-3-prozent-rueckfaelle-mit-kombitherapie/70478098)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-447b1b525473adde0e03c42d_superior_trial_18/